Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at firstname.lastname@example.org and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
The University of California (UC) has begun accepting proposals for the first phase of the state's precision medicine initiative. UC has $2.4 million in state funding to dole out to two projects and is looking for programs that will yield immediate benefits and develop long-term resources.
Early reviews of Apple's much-discussed smartwatch suggest that anyone wanting to make the device a cornerstone of their health or research programs will need to wait for later versions. The grumbles mainly relate to the accuracy and reliability of Apple Watch's heart rate monitor.
GlaxoSmithKline has shone in a ranking of the social media savvy of the 100 largest publicly traded firms in the United Kingdom. The Big Pharma ranked second on the list, an outcome that suggests at least some drugmakers compare favorably to their peers in other industries.
Legislation that would mandate the creation of a system to share de-identified clinical trial data has moved a step closer to coming into force. The text is included in the latest draft of the 21st Century Cures Act, which is almost 200 pages shorter than the original proposal.
Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.
DNAnexus has snagged $15 million from WuXi PharmaTech in a Series D round. The deal will see DNAnexus bring its cloud-based genomics platform to China and pair it with WuXi NextCODE's offering.
Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.
Edico Genome has hooked up with Intel in an attempt to shave more minutes off the time it takes to analyze a whole genome. The partnership brings together Edico's NGS analysis hardware and the Intel Xeon microprocessors that reside in many servers used in genomics.
Quest Diagnostics has teamed up with French human health research institute Inserm to pool and share BRCA1 and BRCA2 genetic data. LabCorp has signed up as the first participant in the program, giving it a sizable reach from day one.
Bina Technologies has unveiled its first publicly known deal with a Big Pharma since it was bought by Roche. The agreement sees AstraZeneca tighten its ties to the genomic data analysis platform provider by becoming the first member of the Bina Alliance Program.